Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
160,3 EUR | +1,42% |
|
+0,24% | +14,72% |
Métier
La répartition géographique du CA est la suivante : Etats-Unis (77,1%), Allemagne (2,3%), Canada (2%), Japon (1,9%), Chine (1,7%), France (1,4%), Espagne (0,9%), Italie (0,9%), Australie (0,9%), Brésil (0,8%), Royaume Uni (0,8%) et autres (9,3%).
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Immunology
48,1
%
| 28 924 | 49,8 % | 26 136 | 48,1 % | -9,64% |
Neuroscience
14,2
%
| 6 528 | 11,2 % | 7 717 | 14,2 % | +18,21% |
Other
12,6
%
| 7 991 | 13,8 % | 6 841 | 12,6 % | -14,39% |
Oncology
10,9
%
| 6 577 | 11,3 % | 5 915 | 10,9 % | -10,07% |
Aesthetics
9,7
%
| 5 333 | 9,2 % | 5 294 | 9,7 % | -0,73% |
Eye Care
4,4
%
| 2 701 | 4,7 % | 2 415 | 4,4 % | -10,59% |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
77,1
%
| 45 713 | 78,7 % | 41 883 | 77,1 % | -8,38% |
All Other Countries
9,3
%
| 4 837 | 8,3 % | 5 042 | 9,3 % | +4,24% |
Germany
2,3
%
| 1 340 | 2,3 % | 1 266 | 2,3 % | -5,52% |
Canada
2,0
%
| 1 159 | 2,0 % | 1 076 | 2,0 % | -7,16% |
Japan
1,9
%
| 956 | 1,6 % | 1 008 | 1,9 % | +5,44% |
China
1,7
%
| 912 | 1,6 % | 950 | 1,7 % | +4,17% |
France
1,4
%
| 787 | 1,4 % | 780 | 1,4 % | -0,89% |
Spain
0,9
%
| 506 | 0,9 % | 501 | 0,9 % | -0,99% |
Italy
0,9
%
| 444 | 0,8 % | 484 | 0,9 % | +9,01% |
Australia
0,9
%
| 508 | 0,9 % | 472 | 0,9 % | -7,09% |
Brazil
0,8
%
| 430 | 0,7 % | 439 | 0,8 % | +2,09% |
United Kingdom
0,8
%
| 462 | 0,8 % | 417 | 0,8 % | -9,74% |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 01/01/13 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 01/01/13 |
Robert Michael
PSD | President | 53 | 01/01/12 |
Thomas Hudson
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/01/16 |
Chief Operating Officer | 60 | 01/01/13 | |
Todd D. Bosse
IRC | Investor Relations Contact | - | 01/12/21 |
Roopal Thakkar
PRN | Corporate Officer/Principal | - | 01/01/03 |
Kevin Buckbee
AUD | Comptroller/Controller/Auditor | 58 | 01/03/23 |
Perry Siatis
LAW | General Counsel | - | 01/10/22 |
Carrie Strom
PRN | Corporate Officer/Principal | - | 08/05/20 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 01/01/13 |
Edward Rapp
BRD | Director/Board Member | 66 | 01/01/13 |
Director/Board Member | 70 | 01/01/13 | |
Glenn Tilton
BRD | Director/Board Member | 75 | 01/01/13 |
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 01/01/13 |
Thomas Freyman
BRD | Director/Board Member | 69 | 08/05/20 |
William Burnside
BRD | Director/Board Member | 72 | 01/01/13 |
Brett Hart
BRD | Director/Board Member | 54 | 01/01/16 |
Robert Alpern
BRD | Director/Board Member | 73 | 01/01/13 |
Robert Michael
PSD | President | 53 | 01/01/12 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 1 830 102 293 | 1 763 861 636 ( 96,38 %) | 64 234 512 ( 3,510 %) | 96,38 % |
Participations
Nom | Actions | % | Valorisation |
---|---|---|---|
2 749 855 | 6,62% | 3 657 307 $ | |
IM CANNABIS CORP. 5,65% | 757 172 | 5,65% | 431 588 $ |
Coordonnées société
![Adresse AbbVie Inc.(4AB)](https://cdn.zonebourse.com/static/address/111966316.png)
Sociétés du groupe
Nom | Catégorie et Secteur |
---|---|
AbbVie Biopharmaceuticals GmbH Taiwan Branch
| |
AbbVie Research BV
| |
AbbVie Central Finance BV
| |
AbbVie SAS
![]() AbbVie SAS Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., AbbVie SAS is a Colombian company that develops drugs and pharmaceutical products. The company is based in Bogota, Colombia. |
Pharmaceuticals: Major
|
AbbVie Logistics BV
![]() AbbVie Logistics BV Medical DistributorsDistribution Services Part of AbbVie, Inc., AbbVie Logistics BV is a wholesaler of pharmaceutical products. The company is based in Zwolle, Netherlands. |
Medical Distributors
|
AbbVie Finance BV
| |
Pharmacyclics Switzerland GmbH
![]() Pharmacyclics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., Pharmacyclics Switzerland GmbH is a Swiss company that manufactures pharmaceutical products. The company is located in Switzerland. |
Pharmaceuticals: Major
|
AbbVie AS
| |
AbbVie SRO (Slovakia)
![]() AbbVie SRO (Slovakia) BiotechnologyHealth Technology Part of AbbVie, Inc., AbbVie SRO (Slovakia) is a company that engages in research and development in the treatment of serious diseases that affect people's lives. The company is located in Slovakia. |
Biotechnology
|
Secteur
Ventes par activité
Ventes par région
![Consensus](/images/consensus_flch.gif)
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
+55,32% | 815 Md | |
+44,05% | 641 Md | |
-6,75% | 352 Md | |
+13,56% | 314 Md | |
+16,57% | 242 Md | |
+2,04% | 224 Md | |
+13,31% | 218 Md | |
+8,48% | 168 Md | |
-2,81% | 159 Md |
- Bourse
- Actions
- Action ABBV
- Action 4AB
- Société AbbVie Inc.